Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

265
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
265
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

173
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
173

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Adverse symptoms attributed to e-cigarettes over six months among participants of a randomized controlled trial testing nicotine freebase e-cigarettes for smoking cessation - Secondary analysis of the ESTxENDS trial.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2026
Same author

Association between duration or intensity of tobacco smoking and olfactory function: A cross-sectional study among smokers willing to quit smoking.

Tobacco induced diseases·2025
Same author

Pulmonary Hypertension Associated with Interstitial Lung Disease: A Review on Diagnosis and Treatment with a Focus on Emerging Therapies.

Respiration; international review of thoracic diseases·2025
Same author

Pulmonary Hypertension in the Field of Hematological and Oncological Diseases.

Respiration; international review of thoracic diseases·2025
Same author

Efficacy of e-cigarettes for smoking cessation in populations with psychiatric and/or substance use problems: A secondary analysis of a randomized controlled trial.

Tobacco prevention & cessation·2025
Same author

Smoking cessation assistance among pneumologists and thoracic surgeons in Switzerland: a national survey.

Frontiers in health services·2024

相关实验视频

Updated: Jun 28, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

147

[渐进性肺纤维化] 肺纤维化

Rebekka Kleiner1, Susanne Pohle1

  • 1Kantonsspital St. Gallen Klinik für Pneumologie und Schlafmedizin Rorschacher Str. 95 9007 St. Gallen.

Therapeutische Umschau. Revue therapeutique
|April 24, 2024
PubMed
概括
此摘要是机器生成的。

渐进性肺纤维化,是一组肺部疾病,呈现早期症状,如咳和呼吸障碍. 新的抗纤维菌药物为治疗这种疾病提供了治疗选择.

更多相关视频

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

335
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.5K

相关实验视频

Last Updated: Jun 28, 2025

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
07:11

Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis

Published on: May 23, 2025

147
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

335
A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
07:38

A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice

Published on: April 13, 2018

11.5K

科学领域:

  • 肺部病理学 肺部病理学
  • 放射学 放射学是一门学科.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 间歇性肺部疾病 (ILD) 通常表现为咳和呼吸障碍的早期症状.
  • 胸部成像,特别是计算机断层扫描,对于早期检测ILD肺部结构变化至关重要.
  • 渐进性肺纤维化包括一组异质的ILDs与相似的纤维化进展.

研究的目的:

  • 突出早期诊断和治疗渐进性肺纤维化的重要性.
  • 强调管理这些疾病所需的跨学科方法,类似于异常性肺纤维化 (IPF).
  • 引入新的治疗策略,包括抗纤维素药物.

主要方法:

  • 审查当前的诊断成像技术 (CT扫描) 检查间歇性肺部疾病.
  • 在各种形式的肺纤维化中分析疾病进展模式.
  • 评估新兴的抗纤维菌疗法.

主要成果:

  • 早期识别症状 (咳,呼吸不全) 和高级成像是及时诊断的关键.
  • 渐进性肺纤维化需要一个多学科的管理策略.
  • 抗纤维素药物代表了治疗选择的重大进步.

结论:

  • 有效管理渐进性肺纤维化需要早期检测和协作,跨学科的方法.
  • 抗纤维素药物为进展性肺纤维化患者提供了新的希望.
  • 对ILD及其治疗的持续研究至关重要.